Kite Pharma (USA) has an approved T-Cell therapy. I believe it is 100k per treatment. It has had some success obviously to have been approved but there can be very severe side effects inc. death.
Marker Therapeutics (USA) is developing a T-cell therapy for lymphoma and other Cancers both blood and solid. They will be releasing data on there therapy for pancreatic cancer next month. There process is different than Kites. Early results are superior for Blood cancers, very little side effects and at least on paper about 1/10th the cost of Kites therapy. Hopefully it can be fast tracked.
Novartis also has Kymriah approved and on market. Pioneered in coordination with the UPenn Perelman Center. This will be the future of cancer treatment...very exciting stuff.